We would love to hear your thoughts about our site and services, please take our survey here.
I don't visit the platform very often as I find it rather odd; who has time to pour over content like this on a daily basis? I guess there's always someone desperate to micro-manage. My rare moments do, however, provide clarity. With only occasional visits, devoid of emotion, the bizarre and odd shine like a beacon. Weirdness and unfathomable narrative are like torches in the night. Thornosgold. Wow. What a truly bizarre character.
Every so often I retrace the Avacta journey to sense-check my investment. I read this quote again earlier; there can be no doubt we are close and no doubt it works.
Dr Simon Bennett, Chief Business Officer, Avacta Therapeutics commented:
“Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets.”
If the results contained anything of value ie information that had emerged that could drastically alter the SP, wouldn't they be obliged to issue an RNS? Or are they entitled to hold it back for the meeting and do the big reveal then.
Success lies in the transition to Advanta - the in-house brand. This will drive the margins. They have access to all the factories in China and Korea that other 'leading brands' have so now it's about two things.
1 Quality, price point and driving the Advanta name to improve desirability.
2 Keeping the shelves stocked - leading brands continually fail to deliver product due to delays.
Angling participation has slid a little after Covid but there's enough product being purchased - they need more share through own-product launches - it is pivotal to growth and the sp.
There are clear signs that Advanta SKUs are on the up, continue that trend and be more aggressive with the marketing. Signing some influencers might be a starting point.
https://www.bbc.co.uk/news/health-65042224
It really wouldn't be that hard to write a story of hope about AVCT's trials - Chemo without side effects is some headline - but Zyme and FTI seem reluctant, or unable, to drum up any media interest. Maybe we're not far enough into the trials or maybe our PR teams are hopeless? Which is it.
It could be the cleaner but it says senior scientist. I do appreciate the Amazon comparison although it's hardly a like for like in staff numbers or staff positions. As an investor I am genuinely interested if a senior scientist has something to say. I may take with a pinch of salt but I'm happy to be made aware of it. It may well be a fake review. Who knows.
Personally I found reading statements from employees moderately interesting. Yes, people do moan and groan about necessary change as I have stated, but it is possible some may have insight from within. Just sharing comments that are out there in the public domain; don't shoot the messenger.
3.0
?????
Current Employee
Direction
8 Nov 2022 - Senoir Scientist
Recommend
CEO Approval
Business Outlook
Pros
Good work life balance, good facilities, well treated
Cons
Company seems unsure of direction to take
Advice to Management
Share goals more with all staff not just senior management
The reviews on my business are flawless, but they would be, I'm the author. And right there is the problem with platforms of this kind. That said, Glassdoor can sometimes be an indicator of the state of the tide. The 'new regime' has clearly ruffled feathers and even advocates aren't without observation. And I'm not a 'deramper' - I'm a very patient LTH but prepared to accept not everything is always a bed of roses.
And one of the poorer from the past year - I'm thinking the 'pro' might not be a selling point:
Current Employee, more than 3 years
Awful, incompetent senior management
16 May 2022 - Scientist in Cambridge, England
Recommend
CEO Approval
Business Outlook
Pros
Absolutely dire place to work
Cons
Atrocious ‘new’ labs, incompetent leadership, poor salary, miserable working environment
Advice to Management
Get a grip
This is the best:
Current Employee, more than 1 year
Great place to work
31 Jul 2022 - Scientist in London, England
Recommend
CEO Approval
Business Outlook
Pros
Since moving to the London site in April, the company has shrunk but has continued to be a great place to work alongside friendly and supportive colleagues. The new management has been really supportive and appreciative of everyone and opportunities for promotion are now more likely with the previous management gone. Atmosphere and culture has improved signifcantly. In addition, the labs and the amenities are great and we're even getting free lunch everyday.
When reading these reviews please keep in mind that some of the other more recent ex-employee reviews do not represent the reality of the siuation but rather bitter feelings associated with the move. Furthermore, any employee who chose not to move or to commute to London was given a redundancy package.
Cons
It did feel like the site move could have waited.
Because the company shrank, we are in need of more lab support.
Advice to Management
Focus less on appearances.
Had a quick scan through employee reviews from Avacta, some fairly recent. I appreciate the problem with platforms like Glassdoor, particularly the rants of those who struggle to accept important change in a company, but it doesnt appear a 100% happy ship. https://www.glassdoor.co.uk/Reviews/Avacta-Reviews-E35375.htm
Dear Fergus,
I read with great interest your story about the potential breakthrough in cancer treatment spearheaded by Sahin and Tureci.
Sadly cancer impacts on all our lives in some way and I have numerous friends and family currently losing their long and painful battles.
There are obviously many new treatments being developed for cancer but the one that I was introduced to recently is perhaps the most interesting. As Medical editor it may be relevant to you.
Trials are being conducted around the country and results are due to be published in the coming weeks, but in simple terms the new treatment allows huge doses of chemo, amounts that would normally be fatal, directly into the tumour without it impacting your wellbeing. No sickness; no hair loss; no side effects - just laser guided treatment so powerful it shrinks cancer in ways the world has never seen before.
I thought it may make an interesting story given 50% of us are likely to get cancer in our lifetimes. The treatment is AVA6000 and it is developed by Avacta.
I hear rumour affimers prevent heart attacks and strokes.
https://abstracts.isth.org/abstract/modulation-of-plasmin-inhibitor-activities-using-affimer-technology-improves-the-hypofibrinolytic-environment-in-high-vascular-risk-individuals/
http://everything.explained.today/Tom_Winnifrith/
Nice man.
Said nobody ever.
Drop and drop?
https://link.springer.com/article/10.1007/s00216-022-04078-4
https://eventpilotadmin.com/appinfo.php?project=AACR22&page=Session&id=P12283